UCB (OTCMKTS:UCBJF) Hits New 12-Month Low – Time to Sell?

UCB SA (OTCMKTS:UCBJF) reached a new 52-week low during trading on Thursday. The company traded as low as $219.60 and last traded at $219.60, with a volume of 1 shares. The stock had previously closed at $236.94.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on UCBJF shares. Piper Sandler reiterated a “neutral” rating on shares of UCB in a report on Wednesday, July 22nd. Jefferies Financial Group raised shares of UCB to a “hold” rating in a research note on Monday, August 3rd. Five investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

UCB Price Performance

The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The business’s fifty day moving average is $251.62 and its two-hundred day moving average is $279.18.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on developing and commercializing medicines for severe diseases, particularly in immunology and neurology. The company’s research and development activities target conditions such as inflammatory disorders, epilepsy, and other diseases affecting the central nervous system.

UCB’s portfolio includes Bimzelx (bimekizumab) for certain inflammatory conditions, Cimzia (certolizumab pegol) for immune-mediated diseases, and Fintepla (fenfluramine), Briviact (brivaracetam), Keppra (levetiracetam), and Nayzilam (midazolam) for seizure-related disorders.